title: Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
authors.forename: Canan
authors.initials: C
authors.lastname: Akyuz
authors.forename: G Burca
authors.initials: GB
authors.lastname: Aydin
authors.forename: Aysenur
authors.initials: A
authors.lastname: Cila
authors.forename: Nejat
authors.initials: N
authors.lastname: Akalan
authors.forename: Figen
authors.initials: F
authors.lastname: Soylemezoglu
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cengiz
authors.forename: Nalan
authors.initials: N
authors.lastname: Yazici
authors.forename: Munevver
authors.initials: M
authors.lastname: Buyukpamukcu
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction; D000069283:Rituximab; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab